Low-responders to angiotensin II receptor blockers and genetic polymorphism in angiotensin-converting enzyme

Clinical Nephrology

Volumn 68, Issue 4, 2007, Pages 209-215

  Nonoguchi, H ^a   Nakayama, Y ^a   Shiigai, T ^b   Inoue, T ^a   Inoue, H ^a   Kohda, Y ^a   Honda, Y ^c   Tomita, K ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Toride Kyodo General Hospital   (Japan)

^c Kengun Clinic   (Japan)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Chronic kidney disease; Converting enzyme; Genetic polymorphism angiotensin; Hypertension; Proteinuria

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; SODIUM; TELMISARTAN; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DEATH; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE DURATION; FEMALE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; HUMAN; INDIVIDUALIZATION; KAPLAN MEIER METHOD; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT CARE; PROTEINURIA; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; SYSTOLIC BLOOD PRESSURE; TIME; TREATMENT OUTCOME;

EID: 34948839032     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68209     Document Type: Article

References (27)

1. Andersen S, Tarnow L, Cambien F et al. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/ deletion genotype? Kidney Int. 2002; 62: 192-198.
2. Cao Z, Bonnet F, Candido R et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol. 2002; 13: 1773-1787.
3. Chan JC, Wat NM, So WY et al. Reduction in Endpoints in NIDDM with Angiotensin II Antagonist Losartan Study Investigators. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study. Diabetes Care. 2004; 27: 874-879.
4. Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res. 2006; 98: 463-471.
5. Esnault VL, Ekhlas A, Delcroix C et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol. 2005; 316: 474-481.
6. Jacobsen P, Tarnow L, Carstensen B et al. Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol. 2003a; 14: 2843-2850.
7. Jacobsen P, Andersen S, Jensen BR et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in Type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003b; 14: 992-999.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
9. Kario K, Hoshide S, Umeda Y et al. Angiotensinogen and angiotensin-converting enzyme genotypes, and day and night blood pressures in elderly Japanese hypertensives. Hypertens Res. 1999; 22: 95-103.
10. Kincaid-Smith P, Fairley KF, Packham D. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. Nephrol Dial Transplant. 2004; 19: 2272-2274.
11. Kurland L, Melhus H, Karlsson J et al. Angiotensin-converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor Type 1 antagonist treatment in hypertensive patients. J Hypertens. 2000; 19: 1783-1787.
12. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med. 2001; 345: 851-860.
13. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 1985; 27: 58-65.
14. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996; 334: 939-945.
15. Mitch WE, Walser M, Buffington GA et al. A simple method of estimating progression of chronic renal failure. Lancet. 1976; 2: 1326-1328.
16. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomized controlled trial. Lancet. 2003; 361: 117-127.
17. Narita I, Goto S, Saito N et al. Renoprotective efficacy of renin-angiotensin inhibitors in IgA nephropathy is influenced by ACE A2350G polymorphism. J Med Genet. 2000; 40: e130-e138.
18. Nonoguchi H, Kiyama S, Inoue H et al. Angiotensin-converting enzyme inhibitor withdrawal and ACE gene polymorphism. Clin Nephrol. 2003a; 60: 225-232.
19. Nonoguchi H, Nakayama Y, Shiigai T et al. Combination therapy with ACE-I and ARB and ACE gene polymorphism. J Am Soc Nephrol. 2003b; 14: 293A (abstract).
20. Parving H-H, Jacobsen P, Tarnow L et al. Effect of deletion polymorphism o f angiotensin-converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin-converting enzyme: observational follow-up study. Br Med J. 1996; 313: 591-594.
21. Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86: 1343-1346.
22. Ruggenenti P, Perna A, Gherardi G et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet. 1998; 352: 1252-1256.
23. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE inhibition in nondiabetic nephropathies with nonnephrotic proteinuria. Lancet. 1999; 354: 359-364.
24. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001; 357: 1601-1608.
25. van Essen GG, Rensma PL, de Zeeuw D et al. Association between angiotensin-converting enzyme gene polymorphism and failure ofrenoprotective therapy. Lancet. 1996; 347: 94-95.
26. van Lier JJ, van Heiningen PN, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens. 1997; 11 (Suppl 2): 27-28.
27. Zhu X, Bouzekri N, Southam L et al. Linkage and association analysis of angiotensin I-converting enzyme (ACE) gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet. 2001; 68: 1139-1148.